合成生物学市场－全球产业规模、份额、趋势、机会及预测（依技术、产品、最终用户、地区及竞争格局划分，2021-2031年）

全球合成生物学市场预计将从 2025 年的 128.1 亿美元成长到 2031 年的 180.6 亿美元，复合年增长率为 5.89%。

该领域专注于设计生物建构模组，以改造现有生物系统，使其具备新的功能或带来实际效益。市场成长的主要驱动力是DNA定序和合成成本的大幅降低，以及工业界对可再生生物基替代品（例如传统化学品和材料）日益增长的需求。这些结构性驱动因素满足了供应链韧性和环境永续性的关键需求，使该领域区别于瞬息万变的技术趋势，并为长期发展奠定了坚实的基础。

然而，生物製造在扩充性仍面临许多挑战，从实验室环境到商业化生产，存在着复杂的技术和经济难题。儘管有这些限制，投资活动依然强劲，凸显了相关人员对该领域商业性潜力的坚定信心。根据SynBioBeta的数据，到2024年，全球合成生物学领域的创投将达到122亿美元，这标誌着金融信心的恢復以及推动这些技术走向市场成熟的持续努力。

市场驱动因素

人工智慧 (AI) 和机器学习的融合正成为推动全球合成生物学市场变革的驱动力，从根本上改变了生物工程的速度和精确度。这些计算工具能够对复杂的生物系统进行预测建模，使研究人员无需进行大量的试验实验即可设计新型蛋白质及其相互作用。这种技术融合显着加速了药物发现和材料科学领域的应用，使以往难以高效分析的生物数据得以有效解读。例如，GoogleDeepMind在2024年5月的一篇部落格报导中报告称，其AlphaFold 3模型在蛋白质交互作用预测的准确率方面比以往的方法至少提高了50%。这项改进转化为更低的开发成本和更短的开发週期，从而促进了更广泛的工业应用。

此外，政府拨款和私人投资的增加正在推动市场成长，为实验室阶段的创新成果实现商业化规模提供了所需的资金。公共部门的各项措施日益重视生物工程，以增强国家供应链的韧性和生物安全，而私人资本则瞄准那些展现出盈利和规模化潜力的公司。例如，英国研究与创新署（UKRI）于2024年11月宣布投资580万英镑，用于支持种子计画和概念验证计划，以实现生物工程领域突破性成果的商业化。这项资金投入势头凸显了全球对合成DNA和基因组工具日益增长的需求，推动了该产业的扩张。 Twist Biosciences公司就是一个例证，该公司在2024财年创下了3.13亿美元的年营收纪录。

市场挑战

生物製造的可扩展性是全球合成生物学市场扩张面临的最大结构性障碍。从实验室规模的实验到工业级商业化的过渡带来了复杂的技术挑战，因为生物系统在大规模生产中往往会表现出不稳定的行为和产量下降。这种技术上的不可预测性使得企业难以实现与现有石化企业竞争所需的单位成本优势。此外，全球供应链缺乏合适的配套基础设施，迫使创新者依赖老旧的製药设施，而这些设施并不适合工业化学品和食品配料所需的低利润成本结构。

基础设施短缺导致市场满足商业性需求的能力出现显着差距。根据 SynBioBeta 预测，到 2024 年，该产业将面临严重的产能短缺，全球发酵产能需求将比现有产能高出约 10 到 100 倍，具体倍数取决于生产规模。这种频宽的短缺直接阻碍了合成生物学技术的市场应用，导致产品上市严重延迟，并限制了该行业的产生收入能力。

市场趋势

酶促DNA合成技术的兴起正在改变市场格局，高效的酶促生产过程正在取代传统的化学亚磷酰胺法。这项转变满足了代谢工程和基因组学研究对长而复杂的DNA序列的迫切需求，同时避免了使用有害的有机溶剂。该技术的快速成熟正吸引大量资金流入能够提供商业规模解决方案的公司，从而推动了传统化学工艺的淘汰。例如，安莎生物技术公司（Ansa Biotechnology）在2025年10月的新闻稿中宣布，已完成超额认购的5,440万美元B轮资金筹措，用于扩展其专有的酵素合成平台，凸显了该产业向永续生产标准的转变。

此外，合成生物学在细胞农业领域的商业化正超越研究阶段，越来越多的公司正在筹集大量资金筹措以扩大营运规模并进入全球食品市场。这一趋势反映出，企业正着力实现与传统肉类生产相当的单位经济效益，并透过与专业投资银行合作来加速市场准入。主要企业从试点设施转向工业化生产，以满足消费者对永续蛋白质来源的需求，这清楚地展现了这一进展。 2025年11月，Meatable宣布与一家投资银行合作完成3,000万欧元的资金筹措，巩固了其作为全球培养肉领导者的地位。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球合成生物学市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按技术（次世代定序技术、PCR技术、基因组编辑技术、生物製程技术、其他技术）
  • 副产品（寡核苷酸/寡核苷酸丛集和合成DNA、酵素、克隆技术试剂盒、异源核酸、底盘生物体）
  • 依最终用户（生技/製药公司、学术/政府研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美合成生物学市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲合成生物学市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区合成生物学市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲合成生物学市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲合成生物学市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球合成生物学市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bota Biosciences Inc.
• Codexis, Inc.
• Enbiotix, Inc.
• Illumina, Inc.
• Merck Kgaa（Sigma-Aldrich Co. Llc）
• Pareto Bio, Inc.
• Scarab Genomics, Llc
• Synthego Corporation
• Synthetic Genomics Inc.
• Thermo Fisher Scientific, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Synthetic Biology Market is projected to expand from USD 12.81 Billion in 2025 to USD 18.06 Billion by 2031, reflecting a compound annual growth rate of 5.89%. This field focuses on engineering biological components to develop new functionalities or modify existing biological systems for practical utility. The market's growth is primarily underpinned by dramatic reductions in DNA sequencing and synthesis costs, alongside rising industrial demand for renewable, bio-based substitutes for traditional chemicals and materials. These structural drivers establish a firm foundation for long-term progress, differentiating the sector from fleeting technological trends by addressing critical needs in supply chain resilience and environmental sustainability.

However, the industry faces a significant obstacle regarding the scalability of biomanufacturing, as moving from laboratory settings to commercial production presents intricate technical and economic difficulties. Despite these constraints, investment activity remains robust, underscoring strong stakeholder confidence in the sector's commercial possibilities. Data from SynBioBeta indicates that in 2024, global venture capital investment in synthetic biology reached $12.2 billion, signaling renewed financial confidence and an ongoing dedication to advancing these technologies toward market maturity.

Market Driver

The integration of artificial intelligence and machine learning acts as a transformative driver for the global synthetic biology market, fundamentally changing the pace and precision of biological engineering. These computational tools facilitate the predictive modeling of intricate biological systems, enabling researchers to design new proteins and interactions without the need for extensive trial-and-error experimentation. This technological convergence notably accelerates applications in drug discovery and material science by interpreting biological data previously considered too complex for efficient analysis. For instance, Google DeepMind reported in a May 2024 blog post that its AlphaFold 3 model achieved at least a 50% increase in prediction accuracy for protein interactions compared to earlier methods, a level of precision that lowers development costs and timelines, thus promoting wider industrial adoption.

Furthermore, rising government funding and private investment are accelerating market growth by supplying the capital needed to scale innovations from the laboratory to commercial viability. Public sector initiatives are increasingly prioritizing engineering biology to bolster national supply chain resilience and biosecurity, while private capital targets companies demonstrating revenue potential and operational scalability. As an example, UK Research and Innovation announced a £5.8 million investment in November 2024 to support seed and proof-of-concept projects for commercializing engineering biology breakthroughs. This financial momentum drives the sector's expansion, as demonstrated by Twist Bioscience, which reported a record fiscal year revenue of $313.0 million in 2024, emphasizing the growing global demand for synthetic DNA and genomic tools.

Market Challenge

Scalability in biomanufacturing constitutes the most significant structural barrier to the expansion of the Global Synthetic Biology Market. The transition from laboratory-scale experiments to industrial-grade commercialization creates complex technical hurdles, as biological systems often demonstrate unstable behaviors and diminished yields when scaled up to larger volumes. This technical unpredictability makes it difficult for companies to attain the unit economics required to compete with established petrochemical products. Additionally, the global supply chain faces a shortage of fit-for-purpose infrastructure, compelling innovators to depend on aging pharmaceutical facilities that are ill-suited for the low-margin cost structures necessary for industrial chemicals or food ingredients.

This infrastructure deficit has resulted in a measurable gap in the market's capacity to satisfy commercial requirements. According to SynBioBeta, the industry faced a critical shortfall in 2024, with global demand for fermentation capacity outstripping available supply by approximately 10 to 100 times, depending on the scale of production. This scarcity of manufacturing bandwidth causes significant delays in product launches and limits the industry's revenue-generating capability, thereby directly impeding the wider market adoption of synthetic biology technologies.

Market Trends

The shift toward Enzymatic DNA Synthesis Technologies is reshaping the market by replacing traditional chemical phosphoramidite methods with efficient, enzyme-based manufacturing. This transition meets the critical demand for longer, more complex DNA sequences essential for metabolic engineering and genomic research while simultaneously removing the need for hazardous organic solvents. The rapid maturation of this technology is driving significant capital allocation toward companies capable of delivering commercial-scale solutions, validating the industry's move away from legacy chemical processes. For instance, Ansa Biotechnologies announced in an October 2025 press release that it secured an oversubscribed $54.4 million Series B funding round to expand its proprietary enzymatic synthesis platform, underscoring the sector's pivot to this sustainable production standard.

Additionally, the commercialization of synthetic biology within cellular agriculture is advancing beyond the research phase, with companies securing substantial funding to scale operations and penetrate global food markets. This trend reflects a strategic focus on establishing unit economics that rival conventional meat production, supported by specialized investment banking partnerships designed to expedite market entry. This progression is evident as leading players transition from pilot facilities to industrial-grade output to meet consumer demand for sustainable protein sources. In November 2025, Meatable announced a partnership with an investment bank to place €30 million of capital, aiming to establish the firm as a global leader in the cultivated meat sector.

Key Market Players

• Bota Biosciences Inc.
• Codexis, Inc.
• Enbiotix, Inc.
• Illumina, Inc.
• Merck Kgaa (Sigma-Aldrich Co. Llc)
• Pareto Bio, Inc.
• Scarab Genomics, Llc
• Synthego Corporation
• Synthetic Genomics Inc.
• Thermo Fisher Scientific, Inc.

Report Scope

In this report, the Global Synthetic Biology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Synthetic Biology Market, By Technology

• NGS Technology
• PCR Technology
• Genome Editing Technology
• Bioprocessing Technology
• Other Technologies

Synthetic Biology Market, By Product

• Oligonucleotide/Oligo Pools and Synthetic DNA
• Enzymes
• Cloning Technologies Kits
• Xeno-Nucleic Acids
• Chassis Organism

Synthetic Biology Market, By End user

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Others

Synthetic Biology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Synthetic Biology Market.

Available Customizations:

Global Synthetic Biology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Synthetic Biology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (NGS Technology, PCR Technology, Genome Editing Technology, Bioprocessing Technology, Other Technologies)
  • 5.2.2. By Product (Oligonucleotide/Oligo Pools and Synthetic DNA, Enzymes, Cloning Technologies Kits, Xeno-Nucleic Acids, Chassis Organism)
  • 5.2.3. By End user (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Synthetic Biology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Synthetic Biology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Synthetic Biology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Synthetic Biology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By End user

7. Europe Synthetic Biology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Synthetic Biology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By End user
  • 7.3.2. France Synthetic Biology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Synthetic Biology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Synthetic Biology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Synthetic Biology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By End user

8. Asia Pacific Synthetic Biology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Synthetic Biology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By End user
  • 8.3.2. India Synthetic Biology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Synthetic Biology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Synthetic Biology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Synthetic Biology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By End user

9. Middle East & Africa Synthetic Biology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Synthetic Biology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Synthetic Biology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Synthetic Biology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By End user

10. South America Synthetic Biology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Synthetic Biology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Synthetic Biology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Synthetic Biology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Synthetic Biology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bota Biosciences Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Codexis, Inc.
• 15.3. Enbiotix, Inc.
• 15.4. Illumina, Inc.
• 15.5. Merck Kgaa (Sigma-Aldrich Co. Llc)
• 15.6. Pareto Bio, Inc.
• 15.7. Scarab Genomics, Llc
• 15.8. Synthego Corporation
• 15.9. Synthetic Genomics Inc.
• 15.10. Thermo Fisher Scientific, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer